Lupus drug pipeline faces important late-stage setbacks

Immunovant discontinued imeroprubart (IMVT-1402) after a Phase 2b cutaneous-lupus study missed its primary endpoint, while Roivant reported a Phase 2b failure for an FcRn drug. Sparse public detail limits interpretation, but the setbacks temper enthusiasm around promising mechanisms and underscore the need for complete efficacy, safety, and subgroup data.